Pasithea Therapeutics announced its participation as an exhibitor at the Children's Tumor Foundation 2026 NF Conference in Denver, focusing on its lead drug candidate PAS-004 for treating neurofibromatosis type 1 (NF1). PAS-004, a next-generation MEK inhibitor, recently received FDA Fast Track and Rare Pediatric Disease designations, highlighting its potential to address NF1-associated plexiform neurofibromas. The company is conducting Phase 1 trials for PAS-004 in both advanced cancer and NF1 patients, aiming to develop safer, long-term therapies. Engagement with the NF1 community at the conference supports Pasithea's mission to improve patient outcomes through collaboration and innovation.
Oramed Pharmaceuticals Inc. will be added to the Russell 2000 and Russell 3000 indexes following the 2026 Russell indexes semi-annual reconstitution, effective June 29, 2026. This inclusion reflects Oramed's ranking among the 4,000 largest U.S. stock...
South Korea, though small in size, has become a major winner in the 2026 AI boom thanks to its dominance in high-bandwidth memory (HBM) production. Key companies SK Hynix and Samsung Electronics, which together make up nearly half of the iShares MSCI...
Lake Victoria Gold Ltd. has appointed key finance and compliance officers in Tanzania to support the transition of its fully permitted Imwelo gold project from planning to construction and production. The Imwelo project, located near AngloGold Ashant...
Quantum Secure Encryption Corp., a Vancouver-based post-quantum cybersecurity firm, announced a partnership with a Malaysian digital certification authority to develop a localized version of its Quantum Preparedness Assessment platform. This move aim...
Intrado introduced a new portfolio of AI-enabled, cloud-native emergency communication solutions designed to help Public Safety Answering Points (PSAPs) improve efficiency, resiliency, and reduce telecommunicator workload. The offerings include VIPER...
